Law Firms Seek Lead Plaintiffs in ImmunityBio Securities Lawsuits

The filings follow an FDA warning on Anktiva promotions.

Overview

Two plaintiff firms, the Schall Law Firm and DJS Law Group, announced they are recruiting ImmunityBio investors to seek lead-plaintiff roles in newly filed stock‑fraud cases.
The suits define a class period from January 19 to March 24, 2026 and set May 26, 2026 as the deadline to ask the court for lead‑plaintiff appointment.
The complaints allege ImmunityBio misled investors by overstating what its drug Anktiva can do for patients with a form of non‑muscle invasive bladder cancer.
The litigation traces to an FDA Warning Letter issued March 13 and publicized March 24 that faulted a TV ad and a podcast for implying broader or curative effects, and the disclosure lined up with a sharp share drop cited by investors.
The class has not been certified, outcomes remain uncertain, and the press releases are attorney advertising inviting investors who say they lost money to contact the firms.